These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8611051)

  • 21. Informing patients with cancer of "new findings" that may influence their willingness to participate in research studies.
    Markman M
    Cancer; 2003 Sep; 98(5):885-7. PubMed ID: 12942552
    [No Abstract]   [Full Text] [Related]  

  • 22. Varieties of uncertainty and the validity of informed consent.
    Weinfurt KP
    Clin Trials; 2008; 5(6):624-5; discussion 630. PubMed ID: 19029211
    [No Abstract]   [Full Text] [Related]  

  • 23. Seeking informed consent to cancer clinical trials; evaluating the efficacy of doctor communication skills training.
    Brown RF; Butow PN; Boyle F; Tattersall MH
    Psychooncology; 2007 Jun; 16(6):507-16. PubMed ID: 16986176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testing an alternate informed consent process.
    Yates BC; Dodendorf D; Lane J; LaFramboise L; Pozehl B; Duncan K; Knodel K
    Nurs Res; 2009; 58(2):135-9. PubMed ID: 19289935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reasons given by patients for participating, or not, in Phase 1 cancer trials.
    Catt S; Langridge C; Fallowfield L; Talbot DC; Jenkins V
    Eur J Cancer; 2011 Jul; 47(10):1490-7. PubMed ID: 21454072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ethical issues in phase I clinical trials.
    Daugherty CK
    Clin Adv Hematol Oncol; 2004 Jun; 2(6):358-60. PubMed ID: 16163205
    [No Abstract]   [Full Text] [Related]  

  • 27. [Ethical and legal problems of medical responsibility in drug trials (author's transl)].
    Nicolas F; Nicolas G
    Anesth Analg (Paris); 1980; 37(9-10):605-6, 609-11. PubMed ID: 7469077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option?
    Miller FG; Joffe S
    Clin Trials; 2008; 5(6):617-23. PubMed ID: 19029210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comment regarding benefit in phase 1 oncology trials.
    Morse M
    Clin Trials; 2008; 5(6):626; discussion 630. PubMed ID: 19029212
    [No Abstract]   [Full Text] [Related]  

  • 30. Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication.
    Meropol NJ; Weinfurt KP; Burnett CB; Balshem A; Benson AB; Castel L; Corbett S; Diefenbach M; Gaskin D; Li Y; Manne S; Marshall J; Rowland JH; Slater E; Sulmasy DP; Van Echo D; Washington S; Schulman KA
    J Clin Oncol; 2003 Jul; 21(13):2589-96. PubMed ID: 12829680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long term clinical trials: how much information do participants retain from the informed consent process?
    Griffin JM; Struve JK; Collins D; Liu A; Nelson DB; Bloomfield HE
    Contemp Clin Trials; 2006 Oct; 27(5):441-8. PubMed ID: 16798101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient satisfaction with an informed consent process.
    Agre P; McKee K; Gargon N; Kurtz RC
    Cancer Pract; 1997; 5(3):162-7. PubMed ID: 9171552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patients' perceptions of informed consent in acute myocardial infarction research: a Danish study.
    Gammelgaard A; Rossel P; Mortensen OS;
    Soc Sci Med; 2004 Jun; 58(11):2313-24. PubMed ID: 15047087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence].
    Kusaba H; Tamura T
    Gan To Kagaku Ryoho; 2000 May; 27(5):775-8. PubMed ID: 10832451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comprehensive primer of surgical informed consent.
    Jones JW; McCullough LB; Richman BW
    Surg Clin North Am; 2007 Aug; 87(4):903-18, viii. PubMed ID: 17888788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Descriptions of benefits and risks in consent forms for phase 1 oncology trials.
    Horng S; Emanuel EJ; Wilfond B; Rackoff J; Martz K; Grady C
    N Engl J Med; 2002 Dec; 347(26):2134-40. PubMed ID: 12501226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Informed consent: patient information forms in chemotherapy trials.
    White DR; Muss HB; Michielutte R; Cooper MR; Jackson DV; Richards F; Stuart JJ; Spurr CL
    Am J Clin Oncol; 1984 Apr; 7(2):183-90. PubMed ID: 6702721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Communication about the risks and benefits of phase I pediatric oncology trials.
    Hazen RA; Zyzanski S; Baker JN; Drotar D; Kodish E
    Contemp Clin Trials; 2015 Mar; 41():139-45. PubMed ID: 25638751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy: helping patients to know the drugs they are receiving and their possible side effects.
    Dodd MJ; Mood DW
    Cancer Nurs; 1981 Aug; 4(4):311-8. PubMed ID: 6911058
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.